Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab for muscle wasting after hip fracture surgery
2013-003439-31Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in muscle atrophy and muscle disuse atrophy comparing bimagrumab with placebo (2 arms). Primary endpoint: Change from baseline to week 24 in total lean body mass. Started May 2014; status: completed.
02
Drugs
bimagrumab
03
Conditions
muscle atrophymuscle disuse atrophy
Beyond the preview
Go deeper on 2013-003439-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003439-31.